市场调查报告书
商品编码
1159261
身体轴性脊椎关节炎治疗药的全球市场(2022年~2028年)Axial Spondyloarthritis Drug Market 2022-2028 |
全球体轴性脊椎关节炎治疗药的市场规模在预测期间内预计将以4.1%的年复合成长率扩大。市场成长的主要因素有批准的生物仿製药数量的增加和轴突脊柱关节炎患病率上升。
本报告提供全球体轴性脊椎关节炎治疗药市场相关调查,提供市场概要,以及各类型,各流通管道,各地区的趋势,及加入此市场的主要企业简介等资讯。
Global Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)
The global axial spondyloarthritis drug market is anticipated to grow at a substantial CAGR of 4.1% during the forecast period. During the forecast period, the global axial spondyloarthritis drug market is expected to be driven by an increase in the number of approved biosimilars and an increase in the prevalence of axial spondyloarthritis. Furthermore, the increase in research and development activities, and the high unmet need for existing treatment, will benefit the axial spondyloarthritis drug market in the forecast year. The high cost of biologics, on the other hand, is expected to limit the global axial spondyloarthritis drug market.
The global axial spondyloarthritis drug market is segmented based on type and distribution channel. Based on the type, the market is sub-segmented into the certolizumab pegol, etanercept biosimilar, ixekizumab, and others. Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Etanercept Biosimilar is anticipated to have a significant market share in the market. Etanercept Biosimilar is a biological medication that works by suppressing a soluble inflammatory cytokine called tumor necrosis factor (TNF). Etanercept is used to treat rheumatoid, juvenile rheumatoid, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, among other conditions.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a significant share in the market after the Asia Pacific. The region's dominance is due to a higher percentage of total income spent on health care compared to other economies, adequate reimbursement, along with widespread awareness.
The major companies serving the global axial spondyloarthritis drug market include AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Novartis AG, Panacea Biotec Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2020, Novartis AG announced that Secukinumab, an IL-17a inhibitor, had been approved by the US Food and Drug Administration for the treatment of psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Research Methodology
The market study of the global axial spondyloarthritis drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers:
4.3.Global Axial Spondyloarthritis Drug Market by Distribution Channel
4.3.1. Hospital Pharmacies
4.3.2 Retail Pharmacies
4.3.3 Online Pharmacies